Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 795 Results

Title
Intervention Indication Therapeutic Area Year Actions
Vericiguat for chronic heart failure with reduced ejection fraction Vericiguat (BAY1021189; MK-1242) Heart failure (HF) Cardiovascular System 2019 View  |  Download
Venetoclax with dexamethasone for previously treated relapsed/refractory multiple myeloma Dexamethasone (dexamethasone sodium metasulfobenzoate) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2021 View  |  Download
Venetoclax in Combination with Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukaemia – First Line Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2017 View  |  Download
Venetoclax in combination with bortezomib and dexamethasone for relapsed multiple myeloma - second line and beyond Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Venetoclax in combination with a hypomethylating agent or low dose cytarabine for newly diagnosed acute myeloid leukaemia hypomethylating agent , Low-dose cytarabine , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2018 View  |  Download
Venetoclax in addition to ibrutinib for relapsed mantle cell lymphoma – second-line and beyond Ibrutinib (Imbruvica) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Mantle cell lymphoma Haematological Cancer and Lymphomas 2020 View  |  Download
Vemurafenib (Zelboraf) for BRAF V600 mutation positive melanoma; completely resected but at high risk of recurrence Vemurafenib (Zelboraf; PLX4032; R7204; RO5185426; PLX-4032; RG7204) Melanoma Skin Cancer 2017 View  |  Download
Veliparib in Combination with Carboplatin and Paclitaxel for Breast Cancer – First to Third Line Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Veliparib (ABT-888; NSC 737664) Breast cancer Breast Cancer 2017 View  |  Download
Veliparib in addition to carboplatin and paclitaxel for epithelial ovarian, fallopian tube, or primary peritoneal cancer Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Veliparib (ABT-888; NSC 737664) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2018 View  |  Download
Veliparib (ABT-888) with carboplatin and paclitaxel for advanced or metastatic non-squamous (current or former smokers) non-small cell lung cancer Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Veliparib (ABT-888; NSC 737664) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications